Your Global Health Resource

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized primarily by insulin resistance and relative insulin deficiency. It accounts for more than 90% of all diabetes cases worldwide and is often associated with obesity, sedentary lifestyle, aging, and genetic predisposition.

Unlike Type 1 diabetes, where there is an autoimmune destruction of pancreatic β-cells, T2DM involves a progressive decline in insulin sensitivity, especially in muscle, liver, and adipose tissue. Over time, pancreatic β-cell function deteriorates, further contributing to hyperglycemia. Elevated blood glucose levels, if left untreated, can lead to microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular complications (heart attack, stroke, peripheral arterial disease).

Diagnosis

T2DM is diagnosed based on:

• Fasting Plasma Glucose ≥126 mg/dL (7.0 mmol/L)
• 2-Hour Plasma glucose ≥200 mg/dL During an Oral Glucose Tolerance Test
• HbA1c ≥6.5%
• Random Plasma Glucose ≥200 mg/dL in a Symptomatic Patient

Treatment Plan

1. Lifestyle Modification (First-Line Therapy)

• Nutrition Therapy: A balanced, individualized eating plan is essential. Focus is on whole grains, lean proteins, vegetables, healthy fats, and minimizing added sugars. A registered dietitian can guide meal planning using methods such as the Mediterranean or DASH diets.
• Physical Activity: At least 150 minutes per week of moderate-intensity aerobic activity (e.g., brisk walking), along with resistance training twice a week, enhances insulin sensitivity and aids glycemic control.
• Weight Management: A weight loss of 5–10% in overweight or obese patients significantly improves glycemic outcomes and cardiovascular risk.

2. Pharmacologic Therapy

• Metformin remains the first-line pharmacologic treatment unless contraindicated. It lowers hepatic glucose production, improves insulin sensitivity, and has cardiovascular benefits.
• If monotherapy fails, additional agents may be added based on patient-specific factors such as cardiovascular risk, kidney function, and weight.
  • GLP-1 Receptor Agonists (e.g., semaglutide, dulaglutide): Promote weight loss, reduce cardiovascular risk.
  • SGLT2 Inhibitors (e.g., empagliflozin, dapagliflozin): Offer renal and cardiovascular protection, useful in heart failure and chronic kidney disease.
  • DPP-4 Inhibitors, Sulfonylureas, Thiazolidinediones, and insulin may also be considered based on efficacy, cost, and tolerance.

3. Monitoring and Follow-Up

• Regular monitoring of blood glucose and HbA1c (typically every 3–6 months) is essential.
• Annual screenings for diabetic complications (retinopathy, nephropathy, neuropathy).
• Blood pressure, lipid profile, and weight should also be closely monitored and managed.

4. Patient Education and Empowerment

• Diabetes self-management education (DSME) and support (DSMS) help patients understand their condition, medication adherence, glucose monitoring, andhow to respond to hypo/hyperglycemia.
• Mental health support is also crucial, as diabetes is associated with high rates of depression and anxiety.

Conclusion

T2DM requires a multidisciplinary, individualized approach integrating lifestyle changes, pharmacotherapy, and ongoing education. Early intervention and sustained control can prevent complications and improve quality of life. With emerging therapies and patient-centered care models, the outlook for individuals with Type 2 diabetes continues to improve